MECHANISM OF ACTION
TYVASO IS A DIRECT-TO-LUNG, INHALED PROSTACYCLIN MIMETIC1,2
There are 3 therapeutic pathways for the treatment of PAH, and guidelines recommend targeting multiple pathways as the current standard of care. Prostacyclin is one of those pathways.3-5
Naturally produced prostacyclin is a potent vasodilator that has antithrombotic and antiproliferative properties.6 TYVASO works by mimicking the effects of natural prostacyclin.1
The mechanism of action (MOA) of prostacyclin mimetics targets 3 of the pathologic changes that occur in PAH1,7:
-
Vasoconstriction
Prostacyclin mimetics directly dilate pulmonary and systemic arterial vascular beds
-
Platelet aggregation
Prostacyclin mimetics inhibit platelet aggregation
-
Smooth muscle proliferation
Prostacyclin mimetics inhibit smooth muscle cell proliferation
Learn more about the demonstrated safety and benefits of inhaled prostacyclin.
TREAT AT THE SITE OF DISEASE1,2
- TYVASO is delivered directly to the lungs, which are highly vascularized, providing an enormous surface area for drug absorption and an attractive target for drug delivery1,2,8
- TYVASO is inhaled directly to distal airspaces that are in close proximity to pulmonary arterioles affected by PAH9
Direct-to-lung delivery results in higher concentrations in the pulmonary arterial vasculature, which may selectively enhance blood flow for better ventilation and perfusion matching with less off-target exposure.2
TYVASO DEVICES
TYVASO is delivered via 2 device options: a Dry Powder Inhaler (DPI) or a nebulizer.
